Apogee Therapeutics (APGE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 27/100 (MEDIUM), 79.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.27% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?
- AbbVie Completes Acquisition of Apogee Therapeutics
- Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?
- AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
- Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
- AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
- Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?
- Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Multicentre, 2×2 factorial, randomised, open-label trial of neuromodulators and cough control therapy for refractory or unexplained chronic cough: the FORTITUDE trial protocol. — BMJ Open 2026 Sep 18 PMID 42760069
- Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review. — Int J Chron Obstruct Pulmon Dis 2026 PMID 42741717
- Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial. — Lancet 2026 Sep 19 PMID 42705251
- Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. — Lancet Infect Dis 2026 Aug 31 PMID 42673984
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet 2026 Aug 29 PMID 42628554
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Apogee Therapeutics.
Full APGE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.